We are live on ! Find out more
CRL icon

Charles River Laboratories

538 hedge funds and large institutions have $11.7B invested in Charles River Laboratories in 2020 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 185 increasing their positions, 192 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 33

24% more call options, than puts

Call options by funds: $41M | Put options by funds: $33.2M

11% more capital invested

Capital invested by funds: $10.5B → $11.7B (+$1.16B)

9% more funds holding

Funds holding: 492538 (+46)

0.01% more ownership

Funds ownership: 94.14%94.16% (+0.01%)

4% less repeat investments, than reductions

Existing positions increased: 185 | Existing positions reduced: 192

12% less funds holding in top 10

Funds holding in top 10: 1715 (-2)

Holders
538
Holders Change
+46
Holders Change %
+9.35%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-11.76%
% of All Funds
0.27%
New
87
Increased
185
Reduced
192
Closed
33
Calls
$41M
Puts
$33.2M
Net Calls
+$7.84M
Net Calls Change
-$36.9M
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
351
Panagora Asset Management
Massachusetts
$534K +$15.7K +66 +3%
SWP
352
Stratos Wealth Partners
Ohio
$510K -$10.2K -43 -2%
SP
353
Symmetry Partners
Connecticut
$500K +$106K +446 +29%
Axa
354
Axa
France
$500K +$167K +700 +54%
QT
355
Quantbot Technologies
New York
$484K +$462K +1,940 New
CIBC Asset Management
356
CIBC Asset Management
Ontario, Canada
$483K
LNWWM
357
Laird Norton Wetherby Wealth Management
California
$483K +$461K +1,935 New
Bessemer Group
358
Bessemer Group
New Jersey
$458K +$16.2K +68 +4%
IAN
359
Integrated Advisors Network
Texas
$454K +$31.2K +131 +8%
BMCM
360
Bryn Mawr Capital Management
Pennsylvania
$452K
YMRC
361
Yorktown Management & Research Company
Virginia
$450K
IRF
362
IBM Retirement Fund
New York
$450K +$51.4K +216 +14%
CI
363
Cigna Investments
Connecticut
$447K +$41.7K +175 +11%
CAPTRUST Financial Advisors
364
CAPTRUST Financial Advisors
North Carolina
$446K -$169K -709 -28%
Cetera Investment Advisers
365
Cetera Investment Advisers
Illinois
$432K +$412K +1,729 New
ZCA
366
Zeke Capital Advisors
Pennsylvania
$409K +$77.2K +324 +25%
PCM
367
Penserra Capital Management
California
$406K +$387K +1,626 New
CNC
368
Canandaigua National Corp
New York
$405K -$13.8K -58 -3%
TPA
369
Trivium Point Advisory
Connecticut
$393K +$69.5K +292 +24%
AP
370
Advisor Partners
California
$389K +$10.5K +44 +3%
GW
371
GW & Wade
Massachusetts
$389K +$371K +1,558 New
American Century Companies
372
American Century Companies
Missouri
$388K +$369K +1,551 New
CA
373
Cambridge Advisors
Nebraska
$375K -$71.4K -300 -17%
Mitsubishi UFJ Asset Management
374
Mitsubishi UFJ Asset Management
Japan
$375K -$32.6K -137 -8%
DekaBank Deutsche Girozentrale
375
DekaBank Deutsche Girozentrale
Germany
$373K +$357K +1,500 New

CRL Hedge Fund Activity: Q4 2020 in Review

538 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2020, worth a combined $11.7B — up 11% from $10.5B a quarter earlier.

Buyers outnumbered sellers: 87 funds opened new CRL positions and 33 closed out — a net gain of 54 holders — while 185 added to existing stakes and 192 trimmed.

The largest buyer was Ameriprise, adding an estimated $92.5M. The largest seller was Wells Fargo, cutting an estimated $117M.

  • 538 institutional investors held Charles River Laboratories (CRL) as of Q4 2020, up from 492 in Q3 2020.
  • Funds reported $11.7B of Charles River Laboratories stock for Q4 2020, up 11% quarter-over-quarter.
  • 87 funds opened new Charles River Laboratories positions in Q4 2020 and 33 closed out, a net change of +54 holders.
  • The largest Charles River Laboratories buyer in Q4 2020 was Ameriprise, an estimated $92.5M added.
  • The largest Charles River Laboratories seller in Q4 2020 was Wells Fargo, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.